Fulgent Genetics (FLGT) Accounts Payables (2015 - 2026)

Fulgent Genetics has reported Accounts Payables for 12 years, with the latest figure at $15.6 million in Q2 2026.

• Quarterly Accounts Payables fell 17.64% year-over-year to $15.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.6 million (down 17.64% YoY) and the FY2025 annual result came in at $18.7 million, up 1.58% from the prior year.
• Accounts Payables retreated to $15.6 million in Q2 2026 per FLGT's latest filing, from $21.1 million in the prior quarter.
• Over five years, Accounts Payables peaked at $37.1 million in Q2 2022 and troughed at $14.5 million in Q3 2022.
• A 5-year average of $20.0 million and a median of $19.3 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 151.71% in 2022, then sank 44.47% in 2023.
• Over 5 years, Accounts Payables stood at $23.1 million in 2022, then plunged by 33.49% to $15.4 million in 2023, then grew by 19.56% to $18.4 million in 2024, then advanced by 1.58% to $18.7 million in 2025, then declined by 16.61% to $15.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $15.6 million, $21.1 million, and $18.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.